2021年12月21日讯 /生物谷BIOON/ --辉瑞（Pfizer）近日公布了一项事后中期分析报告，数据显示：在治疗5年期间，Vyndaqel（tafamidis ...

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for ...

A phase 3 clinical trial of Alnylam’s subcutaneous, long-acting treatment for transthyretin-mediated (ATTR) amyloidosis has met its primary endpoint. The success sets the RNAi specialist up to file ...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO) announced on Tuesday that the European Commission has granted marketing authorization for BEYONTTRA or acoramidis, the first near-complete TTR stabilizer or ...

“Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient ...

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year. The deal will see Novo pay $100 million in upfront and near-term ...